Zydus Pharmaceuticals Inc has received tentative approval from the US Food and Drug Administration (FDA) to market Pimavanserin capsules in the strength of 34 mg, the company informed in a statement.
Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, it added.
It further mentioned that the drug will be manufactured at the group’s formulation manufacturing facility at SEZ Ahmedabad.